Non-Surgical Management of Male Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A UPOINT-Guided Narrative Review

Abstract

Background

Primary prostate pain syndrome (PPPS), formerly referred to as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent and heterogeneous chronic pain condition characterized by persistent pelvic pain, lower urinary tract symptoms, sexual dysfunction, and substantial psychosocial burden.

Objective

This narrative review summarizes current evidence on the pathophysiology, phenotype-based assessment, and non-surgical management of male CP/CPPS, with emphasis on UPOINT-guided multimodal care.

Methods

Evidence was synthesized from guidelines, systematic reviews, meta-analyses, randomized trials, observational studies, and relevant mechanistic literature addressing CP/CPPS, chronic pelvic pain, UPOINT phenotyping, pharmacological treatment, physical therapy, neuromodulation, and psychological interventions.

Results

CP/CPPS is best understood as a multidimensional syndrome involving inflammation and immune dysregulation, peripheral and central sensitization, microbiome disturbance, autonomic imbalance, and psychosocial amplification. The UPOINT framework translates this heterogeneity into actionable domains and supports targeted combinations of urinary, organ-specific, infection-directed, neurologic/systemic, tenderness-focused, and psychosocial interventions.

Conclusion

Non-surgical management of male CP/CPPS should move toward individualized, phenotype-guided multimodal therapy. In particular, pelvic floor physical therapy (for T phenotype) and neuromodulators/central analgesics (for N phenotype) should be prioritized over empiric monotherapy or prolonged antibiotic use. Future trials should use phenotype-stratified enrollment, standardized outcome measures, and longer follow-up to define optimal combinations and durability of benefit.

Introduction

Primary prostate pain syndrome (PPPS), formerly referred to as chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is one of the most common chronic pain-related conditions encountered in urology and andrology. It is characterized by insidious onset, prolonged symptoms, and a high tendency to recur. The clinical core is persistent or recurrent pain or discomfort in the pelvic region, frequently accompanied by lower urinary tract symptoms (LUTS), sexual dysfunction, sleep disturbance, and emotional distress, all of which impose substantial functional and psychosocial burdens on patients.^1–5

The etiology and pathogenesis of CP/CPPS remain incompletely clarified. Increasing evidence suggests that the syndrome is not caused by a single pathogen or isolated organ abnormality. Instead, it may reflect complex interactions among low-grade inflammation and immune dysregulation, peripheral and central sensitization, endocrine and autonomic dysfunction, microbiome disruption, and psychosocial factors. This multidimensional pathophysiology explains the marked heterogeneity of clinical phenotypes and the inconsistent efficacy of traditional single-drug or single-technique approaches.^6–8

As the understanding of CP/CPPS has evolved, the clinical paradigm has shifted from an empiric, prostate-centered view of “prostatitis” to individualized, phenotype-guided multimodal management. In this framework, the therapeutic goal is not to identify a single universal cause, but to recognize the dominant symptom drivers in each patient and combine targeted interventions accordingly.^3,9,10 This review summarizes the pathophysiological basis, clinical phenotyping systems, and current non-surgical evidence for male CP/CPPS, with emphasis on UPOINT-guided treatment construction and future research directions.

Methodology

We conducted a narrative review to synthesize and critically discuss current evidence on the mechanisms and non-surgical management of male CP/CPPS. Priority was given to clinical guidelines, systematic reviews, meta-analyses, randomized trials, observational studies, and mechanistic studies relevant to CP/CPPS, UPOINT phenotyping, pharmacological therapy, physical and neuromodulatory interventions, pelvic floor rehabilitation, and psychological management.

Targeted searches used combinations of the terms “chronic prostatitis/chronic pelvic pain syndrome”, “CP/CPPS”, “UPOINT”, “NIH-CPSI”, “non-surgical treatment”, “pharmacological intervention”, “extracorporeal shock wave therapy”, “acupuncture”, “neuromodulation”, “pelvic floor physical therapy”, and “cognitive behavioral therapy”. Citation tracking was used to capture additional clinically relevant studies and guidelines.

Because the available literature spans heterogeneous definitions, patient phenotypes, interventions, treatment durations, outcome measures, and follow-up intervals, a formal meta-analysis was not attempted. Instead, the evidence is organized around pathophysiological mechanisms and the UPOINT phenotype domains to support clinically actionable synthesis. NIH-CPSI change, pain outcomes, urinary symptoms, quality of life, safety, and clinical feasibility were considered the most relevant endpoints when interpreting the evidence.

Pathophysiological Basis and Clinical Phenotypes: Interactions Among Inflammation, Neuroimmunity and the Microbiome

Current research increasingly frames CP/CPPS as a complex syndrome involving local tissue abnormalities, nervous system plasticity, and systemic microenvironmental imbalance rather than a disorder driven by a single mechanism. Individual patients differ substantially in inflammatory activity, neural sensitization, microbiome features, autonomic function, and psychosocial load; these differences ultimately translate into diverse clinical phenotypes and variable treatment responses (Figure 1 and Table 1).

Figure 1.

Interacting mechanisms sustaining symptoms in male CP/CPPS.

Table 1.

Major Pathophysiological Mechanisms of Male CP/CPPS and Related Clinical Features

Mechanistic Domain	Core Pathological Changes	Typical Clinical/Phenotypic Features	Representative Evidence Signals	Ref.
Inflammation and immune dysregulation	Low-grade inflammation in the prostate and surrounding tissues; increased proinflammatory cytokines and mast-cell activation	Recurrent pelvic pain, perineal or ejaculatory pain, and inflammatory signs in selected patients; corresponds mainly to organ-specific/infection-related domains	Elevated IL-1β, IL-6, TNF-α, and related mediators in expressed prostatic secretions, seminal plasma, or urine	Qinyu Z,11 Inamura S,12 Moryousef J,13 Chen L,14 Deng AQ,15 Manuel RS,16 Liu Y17
Neural sensitization	Reduced peripheral nociceptor thresholds and amplified central pain processing	Hyperalgesia, allodynia, pain spreading to the lower abdomen, scrotum, or perineum, and sleep or fatigue complaints; corresponds to neurologic/systemic features	Experimental models and imaging studies support peripheral and central sensitization in chronic pelvic pain	Tornic J,18 He H,19 Perkins ME20
Microbiome dysbiosis	Altered gut-prostate and urinary microbiome, impaired barrier function, and systemic low-grade immune activation	Symptoms fluctuating with gastrointestinal complaints, diet, or antimicrobial exposure; may coexist with inflammatory phenotypes	Gut and urinary microbiome studies link dysbiosis with immune activation and symptom severity	Qinyu Z,11 Song S,21 Romano L,22 Cao H,23 MC Suarez Arbelaez JM,24 P Bajic RAD25
Autonomic and psychosocial amplification	Sympathetic-parasympathetic imbalance, sleep disturbance, anxiety, depression, catastrophizing, and fear avoidance	Autonomic symptoms, insomnia, anxiety/depression, high pain vigilance, and reduced adherence; corresponds mainly to psychosocial and neurologic/systemic domains	Heart-rate variability and psychometric studies associate autonomic and psychological burden with symptom severity	Ma X,2 Sandler MD,3 Pena VN,4 He H19

Inflammation and Immune Dysregulation

In a substantial proportion of patients with CP/CPPS, conventional cultures do not identify a clear pathogen, yet low-grade chronic inflammation and immune activation may remain important initiating or maintaining factors. Elevated concentrations of proinflammatory cytokines, such as interleukin-1β, interleukin-6, and tumor necrosis factor-α, have been reported in prostatic tissue, seminal plasma, or urine.^11–14 These mediators may directly contribute to tissue irritation and pain and may also activate peripheral nociceptors, thereby promoting a self-reinforcing cycle of neurogenic inflammation.

Abnormal mast cell activation and degranulation can release histamine, nerve growth factor (NGF), and other mediators that further amplify local inflammation and neural sensitivity.^15–17 This bidirectional inflammation-neural crosstalk provides a mechanistic basis for the differential responses observed with anti-inflammatory and immune-related interventions in selected patients.

Neural Sensitization: Peripheral and Central Plasticity

Chronic pain is the defining feature of CP/CPPS, and its persistence is closely associated with neuroplastic changes. Continued local injury or inflammatory stimulation may induce peripheral and central sensitization, transforming pain from a local organ signal into a persistent neural network state.^18–20

Peripheral sensitization refers to lowered activation thresholds and enhanced responsiveness of nociceptors in the pelvic region. As a result, normally non-noxious stimuli, such as bladder filling, may be perceived as painful. NGF and related mediators can promote nerve fiber growth and increase neural excitability, thereby increasing susceptibility to persistent pain.

Central sensitization involves amplified and prolonged responses of neurons in the spinal cord and brain to incoming signals. It can explain hyperalgesia, allodynia, spread of pain to adjacent regions such as the perineum, lower abdomen, or scrotum, and symptoms beyond the pelvis, including fatigue, sleep disturbance, and cognitive complaints. Central sensitization is therefore a key explanation for why pain may persist after the initial trigger has resolved.

Microbiome Dysbiosis and the Gut-Prostate Axis

The gut-prostate axis provides an emerging perspective for understanding CP/CPPS. Gut microbiome dysbiosis may influence pelvic health through several pathways. First, impaired intestinal barrier integrity may permit bacterial metabolites or endotoxins to enter the circulation, triggering systemic low-grade inflammation that can affect the prostate.^11,21,22 Second, altered microbial communities can modulate host immune responses and may communicate with the central nervous system through pathways such as the vagus nerve, potentially contributing to central sensitization.^11,15,23

In addition to the gut microbiome, the urinary tract and prostate harbor relatively distinct microbial communities.^24,25 Disruption of the local genitourinary microbiome may become a source of persistent low-grade inflammation and may interact with immune activation and neural sensitization.

Autonomic Dysfunction and Psychosocial Amplification

Autonomic dysfunction and psychosocial factors frequently coexist with CP/CPPS. Altered sympathetic-parasympathetic balance, sleep disturbance, anxiety, depression, catastrophizing, and fear-avoidance behavior can amplify pain perception and reduce adherence to treatment. Objective measures such as heart rate variability and patient-reported psychological scales have been linked to symptom severity in male pelvic pain.^2–4,19 These observations support a biopsychosocial approach to assessment and intervention.

Clinical Phenotyping and Assessment: From NIH-CPSI to UPOINT

The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) is widely used in clinical practice and research to quantify symptom burden and treatment response.^1,26,27 It assesses pain, urinary symptoms, and quality of life. A reduction of at least 6 points in the total NIH-CPSI score is commonly considered clinically meaningful.¹ However, symptom scoring alone does not capture the biological and psychosocial heterogeneity of CP/CPPS. Traditional NIH classification places most CP/CPPS patients into category III, which is useful for categorization but insufficient for individualized treatment planning.⁷

The UPOINT system decomposes clinical presentation into six assessable and treatable domains: Urinary symptoms, Psychosocial dysfunction, Organ-specific findings, Infection, Neurologic/systemic features, and Tenderness of muscles.^7,10,11 UPOINT is best understood as a dynamic multidimensional assessment framework rather than a fixed label. It helps clinicians construct an individualized symptom map, identify dominant drivers, and combine interventions according to phenotype burden.

Evidence increasingly supports phenotype-driven management. Integrated clinical, meta-analytic, and experimental evidence suggests that UPOINT-guided multimodal interventions can help a substantial proportion of patients achieve clinically meaningful NIH-CPSI improvement within 6 months.¹¹ This supports a transition from syndrome-level diagnosis to phenotype-stratified treatment and also has implications for future trial design, where enrollment and interventions should be aligned with mechanistically relevant subgroups.

UPOINT-Guided Non-Surgical Treatment: Modular Combination Across Six Phenotypes

The UPOINT system converts the heterogeneity of CP/CPPS into six clinically assessable, intervention-ready domains (Figure 2). Treatment can therefore move from sequential trial-and-error toward modular selection and combination of phenotype-matched interventions. The principal non-surgical strategies, mechanisms, evidence signals, appropriate phenotypes, and practical limitations are summarized in Table 2.

Figure 2.

UPOINT-guided assessment, modular intervention and reassessment pathway for male CP/CPPS.

Table 2.

Non-Surgical Treatment Strategies for CP/CPPS and Phenotype-Targeted Considerations

Treatment Module	Primary Target/Mechanism	Evidence Summary	Best-Fit Phenotype/Patient Profile	Practical Limitations
Alpha-adrenergic antagonists	Relax prostate and bladder-neck smooth muscle; improve voiding dynamics	Systematic reviews support improvement in LUTS, whereas pain relief with monotherapy is inconsistent1,28–30	U phenotype with frequency, urgency, hesitancy, weak stream, or voiding-related discomfort.	Not a stand-alone chronic pain strategy; avoid prolonged empiric use in unselected patients; monitor hypotension and dizziness.
Anti-inflammatory and organ-directed pharmacotherapy	Suppress inflammatory mediators or modulate prostate-local endocrine/microenvironmental factors	NSAIDs may provide short-term relief in selected patients; 5-alpha-reductase inhibitors may help patients with enlargement or androgen-related features29,31–33	O phenotype, objective inflammatory findings, prostate tenderness, or coexisting prostatic enlargement.	Gastrointestinal, renal, and cardiovascular risks limit long-term NSAID use; match treatment to objective findings.
Antimicrobial therapy	Eradicate confirmed or strongly suspected bacterial infection; selected agents may also have anti-inflammatory effects	Clearly effective in NIH category II chronic bacterial prostatitis; only selected short trials are justified in NIH category III34–38	Culture-positive patients or highly selected patients with strong infection-related clues.	Repeated empiric therapy is discouraged because of resistance, adverse events, and microbiome disruption.
Neuromodulators and pain-modulating drugs	Reduce peripheral and central sensitization; address neuropathic pain, sleep, and mood comorbidity	Pregabalin, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors may benefit selected patients with neuropathic/systemic features1,3,31	N phenotype, widespread pain, allodynia, hyperalgesia, sleep disturbance, mood symptoms, or central sensitization features.	Sedation, dizziness, weight gain, sexual effects, and withdrawal issues require individualized dosing and monitoring.
ESWT, acupuncture, electrical stimulation, and neuromodulation	Modulate pelvic tissues and neural pathways; promote analgesic, anti-inflammatory, and repair effects	Network meta-analyses and systematic reviews support ESWT and acupuncture/electroacupuncture for NIH-CPSI and pain reduction; TENS/PTNS and rTMS show promise39–55	Pain-dominant patients with inadequate medication response or preference for non-drug intervention.	Protocols differ substantially; patient selection, treatment parameters, and long-term durability require further study.
Pelvic floor physical therapy and psychological-behavioral interventions	Normalize pelvic floor tone; retrain pain-related cognition and behavior; reduce central sensitization and distress	Systematic reviews support PFPT, biofeedback, manual therapy, CBT, and education for pain, symptoms, quality of life, and distress reduction56–61	T phenotype with pelvic floor tenderness/hypertonicity; P phenotype with anxiety, depression, insomnia, pain catastrophizing, or avoidance.	Requires trained teams, adherence, and sufficient treatment duration; blinding and small sample sizes limit parts of the evidence base.

Abbreviations: LUTS, lower urinary tract symptoms; ESWT, extracorporeal shock wave therapy; PFPT, pelvic floor physical therapy; CBT, cognitive behavioral therapy.

U (Urinary) Phenotype: LUTS and Voiding Dynamics

The urinary phenotype is suggested by frequency, urgency, hesitancy, weak stream, or voiding-related discomfort. Treatment aims to improve LUTS and reduce voiding-associated distress while other active phenotype domains are addressed in parallel.

Alpha-adrenergic antagonists, such as tamsulosin and alfuzosin, remain clinically relevant for patients with LUTS associated with CP/CPPS.^1,3,4,29 Current evidence generally supports improvement in urinary symptoms, but pain relief with alpha-blocker monotherapy is inconsistent; meta-analytic evidence suggests that the analgesic effect may not differ meaningfully from placebo in unselected patients.^1,28,30 Their most rational use is therefore in patients with a prominent UPOINT urinary phenotype rather than as prolonged empiric treatment for all patients.

Selected adjunctive pharmacological options may also be considered. Phosphodiesterase type 5 inhibitors can improve erectile function and may benefit LUTS through improved pelvic perfusion and potential anti-inflammatory effects.^3,62

O (Organ-Specific) Phenotype: Prostatic and Pelvic Local Factors

When local inflammatory signs, prostatic tenderness, or prostate-related symptom patterns are present, anti-inflammatory, endocrine-modulating, or locally targeted approaches may be considered after careful appraisal of expected benefit and risk.

Nonsteroidal anti-inflammatory drugs (NSAIDs) can alleviate symptoms in some patients by suppressing inflammatory mediators, but the overall effect size is limited.^1,3,29 They are most appropriate as part of a multimodal plan for patients with objective inflammatory findings or organ-specific/infection-associated features, rather than as long-term empiric therapy.¹²

The endocrine microenvironment may participate in prostatic inflammation and enlargement. Androgen signaling dysregulation has been implicated in disease development, and 5-alpha-reductase inhibitors have therefore been explored as a strategy to modulate local androgen metabolism in selected patients.^29,31–33

More targeted local interventions are also under investigation. Botulinum toxin A may suppress neurotransmitter release and has shown preliminary benefit in some studies involving intraprostatic or pelvic floor injections for local pain and inflammation.^63–66 The current evidence remains limited, and larger trials are needed to define efficacy and safety, but this strategy illustrates the broader movement toward precision local interventions.

I (Infection) Phenotype: Indications and Boundaries of Antimicrobial Therapy

Antibacterial therapy is the most controversial drug strategy in CP/CPPS. In confirmed chronic bacterial prostatitis (NIH category II), a full antimicrobial course remains foundational.^1,34 In the much larger group of patients with nonbacterial CP/CPPS (NIH category III), repeated or prolonged empiric antibiotic therapy lacks strong high-level support and carries risks of antimicrobial resistance and microbiome disruption.^3,29,35

Because conventional testing may miss atypical or Gram-positive organisms, a short, carefully monitored trial may be reasonable in highly selected patients with infection-related features. However, repeated empirical antibiotic use should be avoided when cultures and clinical indicators do not support infection.^34–38

N (Neurologic/Systemic) Phenotype: Pharmacologic Neuromodulation and Physical/Energy-Based Neuromodulation

When pain has neuropathic characteristics, features of central sensitization are present, or standard therapies provide insufficient benefit, neuromodulatory drugs and physical or energy-based neuromodulatory interventions may be combined to reduce pain intensity and improve function.

Pharmacological research has shifted from broad symptomatic treatment toward mechanism-based intervention. Given the role of central sensitization and neurogenic inflammation in pain chronicity, neuromodulators may be useful in patients with prominent neurologic/systemic features. Pregabalin may provide moderate symptom improvement in some patients, particularly those with neuropathic pain features.^1,3,31 Tricyclic antidepressants and serotonin-norepinephrine reuptake inhibitors may also be considered when sleep disturbance, mood symptoms, and central sensitization are clinically relevant.

However, the efficacy of neuromodulators in CP/CPPS remains heterogeneous, and their use should be guided by individual symptom profiles rather than applied universally. Pregabalin, although effective for several neuropathic pain conditions, has demonstrated limited benefit in unselected CP/CPPS populations. In a randomized controlled trial, pregabalin did not achieve a statistically significant improvement in the primary outcome compared with placebo, although certain secondary outcomes and symptom domains suggested potential benefit in patients with neuropathic pain characteristics. Therefore, careful patient selection is essential, particularly for individuals presenting with neuropathic pain descriptors, allodynia, or evidence of central sensitization.

Dose optimization and tolerability are also critical considerations for neuromodulator therapy. Pregabalin is generally initiated at a low dose and gradually titrated according to efficacy and adverse effects, with dizziness, somnolence, cognitive impairment, and peripheral edema representing common limiting factors. Similarly, tricyclic antidepressants (such as amitriptyline) and serotonin-norepinephrine reuptake inhibitors (such as duloxetine) may require several weeks to achieve maximal analgesic effects, and treatment decisions should balance potential benefits against anticholinergic effects, cardiovascular risks, sleep-related effects, and other tolerability concerns.^67,68

Furthermore, abrupt discontinuation of neuromodulators may result in withdrawal symptoms or rebound exacerbation of pain-related symptoms; therefore, gradual dose reduction is recommended when treatment is discontinued.⁶⁹ Given the modest and variable efficacy observed in CP/CPPS, neuromodulators are best considered as targeted adjunctive therapies within a multimodal framework, particularly for patients with prominent neurologic/systemic features rather than as standalone treatments.

When medication is limited by inadequate efficacy or adverse effects, physical energy and neuromodulatory therapies provide important adjunctive options. These therapies are generally noninvasive or minimally invasive and act on pelvic tissues or neural pathways, with particular advantages for pain reduction.

Extracorporeal shock wave therapy (ESWT) has accumulated increasing evidence in CP/CPPS. Systematic reviews and network meta-analyses suggest that low-energy ESWT improves total NIH-CPSI scores and pain subscores compared with placebo or conventional medication, with some durability of effect.^{39–43,70,71} Potential mechanisms include anti-inflammatory effects, promotion of angiogenesis, tissue repair, and modulation of peripheral nerve sensitivity. Standardization of energy settings, treatment sessions, and long-term follow-up remains necessary.^44,45

Acupuncture and electroacupuncture are also supported by a growing body of evidence. Meta-analyses indicate that these interventions can improve overall response rates and reduce NIH-CPSI total and domain scores compared with sham acupuncture or medication, with relatively mild adverse events.^27,46–52 Their mechanisms may involve modulation of central pain perception and descending inhibitory pathways.⁵³

Peripheral electrical stimulation and neuromodulation provide more direct pathway-based intervention. Transcutaneous electrical nerve stimulation and percutaneous tibial nerve stimulation have shown relatively consistent evidence for pain relief in CP/CPPS.⁵⁴ At the central level, repetitive transcranial magnetic stimulation has shown potential for pelvic pain modulation, although optimal stimulation protocols require standardization.⁵⁵ Broader neuromodulation approaches, including sacral, pudendal, and dorsal genital nerve stimulation, are promising for refractory pelvic pain, but patient selection and long-term outcomes require further study.^72–74

T (Tenderness) Phenotype: Pelvic Floor Rehabilitation and Myofascial Therapy

Pelvic floor hypertonicity, trigger points, tenderness, and functional impairment are the core clinical clues for the tenderness phenotype. Pelvic floor physical therapy (PFPT) focuses on relaxation, manual release, neuromuscular re-education, and functional retraining to interrupt the cycle of pain and muscular guarding (Figure 3).

Figure 3.

Pelvic floor hypertonicity and pain amplification loop targeted by pelvic floor physical therapy.

Within a multimodal treatment plan, PFPT is a key component for patients with the UPOINT tenderness phenotype. Many patients have pelvic floor hypertonicity, which can directly generate pain and may also drive urinary and sexual dysfunction.^56,57 The central objective of PFPT is to identify and correct pelvic floor dysfunction through individualized relaxation, manual release, coordination training, and home exercises.

Biofeedback is an important technique and can be viewed as neuromuscular re-education. By providing real-time visual or auditory feedback, it allows patients to transform unconscious pelvic floor activity into information they can perceive and regulate, helping them learn active relaxation rather than involuntary contraction. Network meta-analytic evidence suggests that biofeedback may improve NIH-CPSI scores more effectively than some conventional medications in selected patients.^58,70

Therapist-delivered manual interventions are also important. Myofascial release and trigger point treatment act on tightened muscle and fascial structures to improve tissue mechanics. Systematic reviews suggest an overall positive trend, although superiority over standard care for pain relief has not always reached statistical significance and the quality of evidence remains limited.⁵⁹ Thiele massage, a manual technique specifically targeting hypertonic pelvic floor muscles and myofascial trigger points, has also been incorporated into pelvic floor physical therapy. Through sustained longitudinal pressure applied along contracted muscle fibers, it is proposed to relieve muscle spasm, reduce trigger point irritability, and improve local tissue mobility. Although several studies have reported improvements in pain and pelvic floor tenderness following Thiele massage, the current evidence is limited by small sample sizes and methodological heterogeneity. Consequently, Thiele massage is generally regarded as an adjunctive component of multimodal pelvic floor rehabilitation, particularly for patients with pelvic floor muscle tenderness or myofascial dysfunction.⁷⁵

Importantly, pelvic floor dysfunction in the UPOINT tenderness phenotype should not be interpreted solely as increased muscle tone or impaired relaxation. Chronic muscle guarding may also lead to adaptive muscle shortening, reduced compliance, and restricted range of motion, which can perpetuate mechanical stress and nociceptive signaling. Therefore, relaxation-based interventions alone may be insufficient in patients with shortened pelvic floor muscles. The updated EAU Chronic Pelvic Pain Guidelines emphasize that targeted stretching exercises should be incorporated into rehabilitation programs to restore muscle length, improve tissue extensibility, and recover normal pelvic floor function.⁷⁶ In clinical practice, stretching is typically combined with diaphragmatic breathing, manual therapy, and neuromuscular retraining to achieve progressive normalization of pelvic floor muscle activity. Evidence from pelvic floor rehabilitation studies suggests that multimodal approaches integrating manual therapy, relaxation training, and individualized exercises may provide greater symptom improvement than isolated interventions, particularly in patients with demonstrable pelvic floor tenderness and myofascial dysfunction.^77,78

Regardless of technique, the shared goal of PFPT is to restore normal pelvic floor function and break the cycle of pain, muscle tension, and dysfunction. Systematic review evidence supports PFPT for chronic pelvic pain driven by pelvic floor hypertonicity, making structured pelvic floor assessment and individualized rehabilitation a core element of contemporary CP/CPPS management.

P (Psychosocial) Phenotype: From Stress Amplification to Pain Neuroscience Education and Behavioral Medicine

Anxiety, depression, catastrophizing, and sleep disturbance can amplify pain perception and reduce treatment adherence. Psychological and behavioral interventions aim to lower stress load, reshape pain-related cognition and behavior, and coordinate with other pain-management modules.

A strategy focused only on pelvic organs and local tissues overlooks a core dimension of chronic pain: emotion, cognition, and behavior. Chronic pain is not merely a physiological signal but also a subjective experience shaped by psychological state. Consistent with the biopsychosocial model emphasized by the EAU, AUA, and ICS guidelines, patient education, self-management strategies, and collaborative decision-making are increasingly recognized as essential components of chronic pelvic pain management. In this context, these approaches are often incorporated under the framework of Pain Neuroscience Education (PNE), or pain science education, which aims to improve patients’ understanding of pain mechanisms, reduce maladaptive beliefs, and enhance active participation in symptom management.⁷⁶ Psychological and behavioral care should therefore be considered a core component for the psychosocial phenotype rather than an optional add-on.

A common clinical loop is persistent pain triggering stress responses, anxiety, depression, and catastrophic interpretation; these negative cognitive and emotional states then heighten central sensitivity to pain signals, making pain stronger and more difficult to control.^2,3 The goal of psychological intervention is to identify and interrupt this loop.

Cognitive behavioral therapy (CBT) is among the best-supported psychological interventions. CBT helps patients identify and modify dysfunctional pain-related thoughts, such as catastrophizing, and behaviors, such as fear-driven avoidance, while building adaptive coping strategies for active symptom management.⁶⁰ Systematic reviews suggest that, although CP/CPPS-specific psychological evidence remains less extensive than in some other pain conditions, psychological care can reduce distress and may improve quality of life and treatment adherence.⁶¹

In addition to structured CBT, Pain Neuroscience Education provides a broader framework for ongoing psychological support, patient education, and self-management. Helping patients understand chronic pain, especially the role of central sensitization, can itself function as cognitive restructuring.⁹ When patients understand that pain does not always equal ongoing tissue injury, fear and anxiety may diminish. Through improved understanding of pain mechanisms and shared decision-making with clinicians, patients may become more actively engaged in pacing, coping strategies, and long-term symptom management.⁷⁹ Empathic and supportive clinician-patient relationships can enhance safety, adherence, and the overall effectiveness of multimodal care.^3,61

Phenotype Combination and Stepwise Follow-Up: From Modular Treatment to an Executable Pathway

Most patients exhibit more than one UPOINT domain. Management should prioritize the strongest and most reversible drivers and then escalate, combine, or de-escalate after reassessment at approximately 4–12 weeks (Figure 2).

UPOINT assessment turns a complex syndrome into a set of actionable therapeutic dimensions. Patients with prominent urinary symptoms may start with alpha-blockers or other LUTS-directed therapies; those with organ-specific inflammation or infection clues may receive time-limited anti-inflammatory or antimicrobial strategies under risk control; patients with neuropathic pain or systemic symptoms may benefit from neuromodulators, ESWT, acupuncture, or neuromodulatory techniques; and patients with pelvic floor tenderness or psychosocial burden should receive PFPT, education, CBT, or other behavioral interventions.

In practice, a structured assessment-intervention-reassessment cycle is recommended. First, quantify baseline symptoms with NIH-CPSI and map the UPOINT domains. Second, address the most prominent and reversible drivers, such as severe LUTS, clear infection or inflammation, pelvic floor dysfunction, or high psychological distress. Third, start universal foundations, including patient education, sleep optimization, graded activity, and realistic goal setting. Finally, reassess NIH-CPSI change, pain interference, urinary symptoms, adverse effects, and patient goals to guide treatment adjustment.

Limitations

Several limitations of this narrative review should be acknowledged. First, as a narrative synthesis, this review was not designed to provide quantitative estimates of treatment effects or formal evidence grading. Although we prioritized clinical guidelines, systematic reviews, meta-analyses, randomized controlled trials, and relevant mechanistic studies, the selection and interpretation of available literature may inevitably involve potential selection bias.

The current evidence base for non-surgical management of male CP/CPPS remains highly heterogeneous. Differences in diagnostic criteria, patient characteristics, UPOINT phenotype distribution, intervention protocols, treatment duration, and outcome measures limit direct comparison across studies and may partially explain inconsistent therapeutic responses. In particular, although UPOINT-guided multimodal therapy provides a rational framework for individualized treatment, robust evidence defining the optimal combination, sequence, and intensity of different phenotype-targeted modules remains insufficient.

Head-to-head comparisons between different UPOINT-based treatment combinations are currently lacking. Most available studies evaluate individual interventions or relatively small multimodal cohorts, making it difficult to determine whether specific therapeutic combinations provide superior efficacy for particular phenotype profiles. Future investigations should incorporate standardized phenotype stratification, adaptive trial designs, and long-term follow-up to establish evidence-based algorithms for personalized CP/CPPS management.

Conclusions and Future Directions

The understanding and clinical management of CP/CPPS have changed substantially in recent years. Care is moving away from prostate-centered monotherapy toward individualized, UPOINT-based multimodal management. This paradigm is grounded in the recognition that inflammation-neuroimmune dysregulation, microbiome disturbance, autonomic imbalance, and psychosocial factors interact to sustain symptoms.

Within this framework, treatment selection is no longer an empiric sequence of isolated trials. Traditional drugs and emerging mechanism-based interventions each have defined boundaries, while physical energy therapies, pelvic floor rehabilitation, neuromodulation, and psychological-behavioral interventions play irreplaceable roles in pain management and functional recovery.

Important challenges remain. Future studies should improve evidence quality through rigorously designed, adequately powered multicenter randomized controlled trials that evaluate long-term efficacy, safety, and optimal combinations of therapies. Adaptive trial designs may be particularly useful for a highly heterogeneous condition. Mechanistic research should further clarify the brain-gut-prostate axis, neuroimaging features of central sensitization, and cellular and molecular pathways that may reveal new therapeutic targets.

The ideal care model for male CP/CPPS is multidisciplinary and adaptive. Urology, pain medicine, physical therapy, psychology, and related disciplines should collaborate to construct and dynamically revise individualized treatment plans. The ultimate goal is to interrupt the cycle of chronic pain, functional dysfunction, and psychological distress and to produce durable improvement in overall quality of life.

Funding Statement

Natural Science Foundation of Zhejiang Province (LMS25C040003); Medical and Health Science and Technology Research Program of Zhejiang Province (2024KY433); Zhejiang Medical Association Clinical Medical Research Fund – Key Project (2023ZYC-Z39); Zhejiang Provincial Multi-disciplinary TCM Innovation Team for the Diagnosis and Treatment of Headache and Vertigo in the Elderly (2022-19); Zhejiang Clinovation Pride – Herpes Zoster Neuralgia (CXTD202502014); Zhejiang Provincial Key Clinical Discipline – Department of Anesthesiology (2023-ZJZK-001); Jiaxing Medical Key Supporting Discipline – Anesthesiology; Jiaxing Provinces and Cities Jointly Cultivate Discipline – General Surgery (Minimally Invasive) (2023-PYXK-001).

Data Sharing Statement

Data sharing is not applicable to this article as no new data were created or analyzed in this narrative review.

Author Contributions

Jingxuan Sun conceived the study, designed the review framework, drafted the manuscript, and critically revised the final version. Shihao Jing contributed to literature retrieval, literature organization, and manuscript preparation. Yong Fei contributed to literature analysis, table preparation, and manuscript revision. Jianjun Zhu supervised the study concept, provided critical intellectual input, revised the manuscript critically, and approved the final version. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure

The authors declare no conflicts of interest.